
Acquisition · Aytu BioPharma
UK's Rosemont Pharmaceuticals to buy Aytu BioPharma for about $56 million
The Leeds-based maker of oral liquid medicines will pay $2.70 a share in cash for the Denver drugmaker behind the depression drug EXXUA and a line of ADHD treatments, a 51.7% premium to Aytu's last close before the deal.




